SCHEMBL1966304

SCHEMBL1966304

CCCc1cc2c(Cl)nc(C(=O)OCC)nc2s1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.40
BRD4 O60885 1/20 0.40
SELE P16581 1/20 0.39
VCAM1 P19320 1/20 0.39
KDM4E B2RXH2 4/20 0.39
HPGD P15428 4/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPT P10636 5/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
ATM Q13315 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KMT2A Q03164 1/20 0.36
IKBKB O14920 1/20 0.36
CDC7 O00311 1/20 0.35
DBF4 Q9UBU7 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL163783 0.84 MAPT (0.40) HSD17B10KDM4EHPGDALDH1A1MAPT
SCHEMBL1965667 0.81 BRD4 (0.38) HSD17B10BRD4SELEVCAM1KDM4E
SCHEMBL1966694 0.78 SELE (0.48) HSD17B10SELEVCAM1KDM4EHPGD
SCHEMBL655312 0.75 KDM4E (0.52) HSD17B10KDM4EHPGDALDH1A1MAPT
SCHEMBL1969648 0.75 SELE (0.45) HSD17B10BRD4SELEVCAM1KDM4E
SCHEMBL11479901 0.75 F2 (0.44) HSD17B10BRD4KDM4EALDH1A1GLA
SCHEMBL164838 0.75 MAPT (0.45) KDM4EHPGDALDH1A1MAPTGAA
SCHEMBL12409516 0.75 BRD4 (0.40) BRD4ALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL1967325 0.74 KDM4E (0.55) HSD17B10BRD4KDM4EHPGDALDH1A1
SCHEMBL8185646 0.73 BRD4 (0.43) HSD17B10BRD4KDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
EP-2334689-A2 FUSED HETEROCYCLIC COMPOUND LG Life Sciences Ltd. (KR) 2011-06-22 EP disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND F2, PF4, F11 HSD17B10 1133/4885BRD4 1782/4885SELE 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.